What is the recommended treatment for perioral movements associated with tardive dyskinesia?

Treatment of Perioral Tardive Dyskinesia

For perioral movements associated with tardive dyskinesia, you should treat with a VMAT2 inhibitor (valbenazine or deutetrabenazine) as first-line therapy, as these are FDA-approved and have Level A evidence for effectiveness. 1, 2

Primary Treatment Algorithm

Step 1: Assess Clinical Severity and Psychiatric Stability

• If the patient is in full psychiatric remission and any medication change risks relapse: continue current antipsychotic at the same dose while adding VMAT2 inhibitor 3
• If the patient is not in full remission or psychiatric stability allows: proceed to Step 2

Step 2: Modify Antipsychotic Regimen

• Lower the dose of the current antipsychotic, OR
• Switch to an atypical antipsychotic (lower TD risk than typical agents) 3

Step 3: Add VMAT2 Inhibitor

First-line pharmacotherapy options (Level A evidence):

• Deutetrabenazine - established as effective 2
• Valbenazine - established as effective 2

These agents work by reducing dopamine signaling dysregulation without directly blocking D2 receptors, making them superior to older approaches 4

Step 4: Alternative Pharmacological Options (if VMAT2 inhibitors unavailable or contraindicated)

Level B evidence (should be considered):

• Clonazepam - probably improves TD 2
• Ginkgo biloba - probably improves TD 2

Level C evidence (might be considered):

• Amantadine 2
• Tetrabenazine (older VMAT2 inhibitor, less selective) 2

Step 5: Refractory Cases

For intractable TD unresponsive to pharmacotherapy:

• Pallidal deep brain stimulation - Level C evidence, possibly improves TD 2
• Unilateral internal globus pallidus stimulation at 60 Hz has shown immediate suppression of perioral involuntary movements 5

Critical Implementation Points

Monitoring requirements:

• Assess for dyskinesias every 3-6 months using the Abnormal Involuntary Movement Scale (AIMS) 3, 4
• Document baseline abnormal movements before starting any antipsychotic 3

Common pitfall to avoid: Do NOT use anticholinergic agents for TD - these are for acute dystonia and drug-induced parkinsonism, NOT tardive dyskinesia 3, 1. Anticholinergics may actually worsen TD symptoms.

Important caveat: Withdrawal dyskinesia (occurring with cessation of antipsychotics) almost always resolves over time, whereas true TD may persist even after discontinuation 3. Distinguish between these entities before committing to long-term VMAT2 inhibitor therapy.

Informed consent: TD has both clinical and medicolegal implications - ensure adequate informed consent is documented before initiating or continuing antipsychotic therapy 3

Why This Approach

The evidence strongly favors VMAT2 inhibitors as first-line treatment because they are the only FDA-approved medications specifically for TD with Level A evidence 1, 2. The 2020 APA guideline explicitly recommends VMAT2 inhibitors for moderate to severe or disabling tardive dyskinesia 1. Older strategies like "watchful waiting" or switching antipsychotics alone have insufficient evidence (Level U) 2, though antipsychotic modification remains important for overall TD management strategy.

The perioral region is the most commonly affected area in TD (orofacial choreic/athetoid movements) 3, making this a typical presentation requiring definitive treatment rather than conservative observation.